The facilities, located in Solna, Stängnäs, Höganäs, Karlskoga, and Uppsala OTC Development in Sweden, Pessac in France, and Parets in Spain, have been integral parts of Recipharm for over a decade. Specializing in the manufacturing and development of oral solid, semi-solid, and liquid dosage form pharmaceutical products, these sites serve a diverse clientele of over 120 customers worldwide, boasting a strong track record of quality and regulatory compliance.

Upon completion of the transaction, these facilities will form a new independent CDMO platform operating under a new corporate identity, to be disclosed post-acquisition. Blue Wolf aims to leverage these assets to enhance manufacturing capabilities and development services, ensuring the continued delivery of high-quality pharmaceuticals to patients globally.

“Blue Wolf is excited for the opportunity to build a new CDMO platform with these seven European assets serving as a cornerstone,” said Shashank Patel, Principal at Blue Wolf. “Partnering with the leadership and teams at these facilities, we look forward to continuing to deliver world-class manufacturing capabilities and development services to our partners in order to provide the highest quality pharmaceuticals to patients around the world.”

Greg Behar, CEO of Recipharm, expressed confidence in the acquisition, stating, “I am confident that Blue Wolf will continue to elevate service excellence and bolster the organization for the benefit of customers and patients.”

The transaction, expected to close in Q4 2024, is subject to customary regulatory approvals. Terms of the agreement were not disclosed.